LS
Lisata Therapeutics, Inc.
LSTA · NASDAQ
$1.64 -3.24% (-$0.06)
1M +38.98%
Market Cap $14.9M
P/E Ratio -
Div. Yield -
ROE 113.79%
Piotroski F-Score Weak
1/9Valuation
46 /100
Fair P/S 149.35x
P/B 1.81x
P/E N/A
Growth
0 /100
Declining Book val. growth 39.35%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 95.00%
FCF margin 12,323.00%
Net margin 14,621.00%
Quality
0 /100
Poor ROIC 199.05%
Asset turnover 0.01x
ROE 113.79%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 3.69x
Int. coverage N/A
Stability
61 /100
Moderate Beta 0.80x
Profitable years 0
EPS volatility 36.23%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na LSTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David J. Mazzo
Employees
21
Headquarters
Basking Ridge
Nadcházející události
05 LIS
Earnings
Upcoming earnings report